The question of to whom and how stem cell transplantation is performed in patients with Acute Myeloid Leukemia (AML) is determined by the patient's risk group. Patients are categorized into low, intermediate, and high-risk groups based on their genetic mutations and chromosomal abnormalities. Stem cell transplantation is generally not preferred for patients in the low-risk group. These patients are primarily treated with chemotherapy and consolidation therapies. In these groups, where the disease course is potentially favorable, stem cell transplantation may be foregone to avoid the serious complication risks associated with the transplant. Patients in the intermediate and high-risk groups are considered for stem cell transplantation only after achieving disease remission.